Redhill Biophrma ADR (RDHL) 15.05 $RDHL RedHill

New Post Public Reply Private Reply Replies (0) Message Board

Sep 2, 2016 at 3:19 PM

Redhill Biophrma ADR (RDHL) 15.05 $RDHL

RedHill Biopharma to Present at the 9th Annual BioPharm America International Partnering Conference
GlobeNewswire - Thu Sep 01, 8:00AM CDT
RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"

, a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that Mr. Adi Frish, RedHill's Senior VP Business Development & Licensing, will be presenting at the 9 Annual BioPharm America International Partnering Conference, on Wednesday, September 14, 2016, at 3:00 pm EDT, at the Boston Marriott Copley Place in Boston, MA.
RDHL: 15.05 (+0.17)

RedHill Biopharma to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
GlobeNewswire - Wed Aug 31, 6:00AM CDT
RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"

, a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that Mr. Guy Goldberg, RedHill's Chief Business Officer, will present a corporate overview at the Rodman & Renshaw 18 Annual Global Investment Conference, on Monday, September 12, 2016, at 3:00 pm EDT, at The Lotte New York Palace Hotel in New York.
RDHL: 15.05 (+0.17)

RedHill Biopharma Announces Approval of a European Patent Supporting RHB-104 for Multiple Sclerosis
Globe Newswire - Mon Aug 29, 7:00AM CDT
- RedHill has received from the European Patent Office a Notice of Intention to Grant a new patent covering RHB-104 for multiple sclerosis (MS), expected to be valid until 2032, once granted
RDHL: 15.05 (+0.17)

RedHill Biopharma Provides 2016 Semi-Annual R&D Update
Globe Newswire - Thu Aug 11, 8:01AM CDT
TEL-AVIV, Israel, Aug. 11, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"

, a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today provided an update on select research and development potential milestones and estimated timelines.
RDHL: 15.05 (+0.17)

RedHill Biopharma Announces Last Patient Visit in Phase IIa Study with RHB-104 for Multiple Sclerosis
Globe Newswire - Mon Aug 01, 7:07AM CDT
- The Phase IIa proof-of-concept study evaluates the safety and potential efficacy of fixed oral dose RHB-104 as an add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (RRMS)
RDHL: 15.05 (+0.17)

Global Gastritis Pipeline Report 2016 - Therapeutics Review of BCWorld Pharm, Daewon Pharm, Recce Limited & RedHill Biopharma Ltd. - Research and Markets
BusinessWire - Fri Jun 24, 5:59AM CDT
Research and Markets has announced the addition of the "Gastritis - Pipeline Review, H1 2016" report to their offering.
RDHL: 15.05 (+0.17)

RedHill (RDHL) Stock Up on Positive Phase I Data on Yeliva
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:11AM CDT
RedHill (RDHL) announced positive results from a phase I study on Yeliva for the treatment of advanced solid tumors.
RDHL: 15.05 (+0.17), ANIP: 59.49 (-1.93), PFE: 34.67 (-0.01), BMY: 56.27 (-0.49)

RedHill Biopharma Announces Publication Demonstrating Potential Efficacy of RHB-104 for Crohn's Disease Associated with MAP Infection
Globe Newswire - Wed Jun 22, 7:00AM CDT
- The peer-reviewed article, authored by scientists from the University of Central Florida, concludes that the triple combination of the RHB-104 active components provides excellent synergistic activity in the inhibition of mycobacterial growth, potentially leading to a new and effective treatment for Crohn's disease associated with Mycobacterium avium subspecies paratuberculosis (MAP) infection
RDHL: 15.05 (+0.17)

RedHill Biopharma Announces Positive Final Results with Primary and Secondary Endpoints Met in Phase 1 Study with YELIVA(TM) in Advanced Solid Tumors
Globe Newswire - Tue Jun 21, 8:31AM CDT
- Final results from the Phase I study with YELIVA(TM) (ABC294640) in patients with advanced solid tumors confirmed that the study, conducted at the Medical University of South Carolina (MUSC), successfully met its primary and secondary endpoints, demonstrating that the drug is well tolerated and can be safely administered to cancer patients at doses that provide circulating drug levels that are predicted to have therapeutic activity
RDHL: 15.05 (+0.17)

RedHill Biopharma Announces First Patients Dosed in Phase II Study with BEKINDA(TM) for IBS-D
GlobeNewswire - Mon Jun 20, 7:00AM CDT
-- The first patients have been dosed in the randomized, double-blind, placebo-controlled Phase II study with BEKINDA 12 mg for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D) in 120 subjects in 12 clinical sites in the U.S.
RDHL: 15.05 (+0.17)

RedHill Biopharma to Present at JMP Securities Life Sciences Conference
GlobeNewswire - Wed Jun 15, 7:00AM CDT
RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"

, a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases and cancer, today announced that Mr. Gilead Raday, RedHill's Chief Operating Officer, will present a corporate overview at the Jefferies 2016 Healthcare Conference, on Wednesday, June 8, 2016, at 10:00 am EDT, in New York, NY.
RDHL: 15.05 (+0.17)

RedHill Biopharma Announces National Cancer Institute Grant Supporting YELIVA(TM) Phase II Hepatocellular Carcinoma Study
Globe Newswire - Wed May 04, 7:22AM CDT
- The $1.8 million U.S. National Cancer Institute (NCI) grant, awarded to the Medical University of South Carolina (MUSC), is intended to support a research program covering a variety of solid tumor cancers, including a Phase II study with YELIVA(TM) (ABC294640) for the treatment of advanced hepatocellular carcinoma, planned to be initiated in Q3/2016 at MUSC and collaborating institutions
RDHL: 15.05 (+0.17)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mango Board Honors Retailers Boosting Mango Sales

The Unsung Heroes of the Mango Aisle You ever look around a grocery store and wonder who's behind those flashy displays that make a mango seem like the most appealing fruit in the aisle? Well, this year, four retailers got their pat on the back from the National Mango Board for doing just that—H-E-B, Rouses, Nugget Market, and Superior Grocers. Let me tell you, these...

ePlus Schedules Q2 2027 Earnings Call Amid Corrections

Earnings Date: Mark Your Calendar Well, folks, the date is set. ePlus Inc. is gearing up to drop some numbers that could stir the markets a bit. Come November 5th, those eagle-eyed investors better be on their toes because that’s when we’re getting the scoop on ePlus' second-quarter results for the fiscal year 2027. The bell rings after the market closes, so pour...

Democracy's Living History at Long Island University

America’s democracy is getting its moment in the spotlight over at Long Island University, and it's more than just statues and old papers. This exhibition, "The Presidency & Promise of America: A More Perfect Union," unpacked on October 28, throws open a window into the U.S.'s democratic journey from its scrappy beginnings to today’s hot zones of political debate. And...

FOX News Sweeps 2026 Midterms Coverage Ratings

FOX News Outshines Rivals in Midterm Coverage Diving into the chaos of the 2026 midterm elections, it’s clear FOX News Media’s strategic playbook outmaneuvered its cable competitors, chalking up a dominant ratings victory. Nielsen's final count places FOX News Channel (FNC) in the spotlight, their primetime broadcast drawing nearly 4.7 million viewers. And while some...

Planet Fitness Flexes Financial Muscle in Q3 2026

Financial Performance and Strategic Shifts Amidst a flurry of strategic maneuvers, Planet Fitness (NYSE: PLNT) cranked out a mixed but promising set of financial results for the third quarter of 2026. Revenue jumped 9.0% from last year to hit $360 million, a solid figure even if it came with a slight decrease in net income. It's a dance between growth and caution, folks....

Gundry MD Unleashes MyoPeptide: A Powerhouse Supplement

Creatine Gets a Makeover with MyoPeptide Well, here we have it! Gundry MD just rolled out their newest concoction, MyoPeptide Complex, and she's not your run-of-the-mill creatine shake. Blending creatine monohydrate with PeptiStrong®, a fava bean peptide, plus a couple of vitamins, this new supplement claims to turbocharge strength, recovery, and even your cognitive...

MDA Space Q3 2026: Growth, Cash Flow Surge

Revving Up in the Space Game Alright, let's talk MDA Space (TSX:MDA). Their third-quarter numbers for 2026 are in, and boy, they're not just floating aimlessly in space—this company is rocketing upward. Revenue hit $498 million, a solid 22% jump from last year. The kind of boost you'd expect when you've got a $40 billion opportunity pipeline and some new shiny tech...

Qfin Faces Stock Lawsuit: Know Your Investor Rights

Qfin in the Legal Hot Seat When you hear about a company's legal wranglings, especially one like Qfin Holdings, Inc., you've got to sit up and take notice. We're not talking about a quick scuffle here; this is a full-blown class action lawsuit with its talons sunk deep into allegations of securities law violations. They're squared off against DJS Law Group, an outfit that...

Co-Diagnostics Moves Up Q3 Earnings Release to Nov. 10

Co-Diagnostics Shifts Its Calendar Well, well, well, Co-Diagnostics decided to shake up its calendar. What are they looking to spill before the weekend? They’ve bumped up their third quarter 2026 earnings release by two days—an eyebrow-raiser for folks watching NASDAQ:CODX. Now they'll lay it all out on November 10, after we wrap up the trading day. I don’t want to...

International Book Launch Celebrates Chinese Garden Art

Book Celebrates the Harmony of Nature and Culture The dusty pages of history crack open yet again, but this time with an aromatic whiff of oriental garden artistry. Some might say books and gardens don't share much beyond paper, mulch, and soil. But hold tight. This isn't just any old launch—it's the Harmony Between the Universe: International Perspectives on the Lion...